Tenax Therapeutics (TENX) Share-based Compensation (2010 - 2026)
Tenax Therapeutics (TENX) reported Share-based Compensation of $2.8 million for Q1 2026, down 29.05% on a YoY basis from $4.0 million in Q1 2025, and down 40.75% sequentially from $4.8 million in Q4 2025.
Tenax Therapeutics (TENX) Share-based Compensation (2010 - 2026) Analysis & Trends
Tenax Therapeutics (TENX) has 14 years of Share-based Compensation data on file, last reported at $2.8 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 29.05% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $17.1 million (up 243.66% YoY), and the FY2025 full-year result was $19.2 million, up 25.25% from the prior year.
- Share-based Compensation slipped to $2.8 million in Q1 2026, from $4.8 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $26.5 million in Q2 2025 to a low of $9000.0 in Q3 2024.
- A 3-year average of $5.0 million and a median of $2.8 million in 2026 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation surged 264900.0% in 2025 and slipped 29.05% in 2026, its largest moves.
- Tracing TENX's Share-based Compensation over 3 years: stood at $965000.0 in 2024, then surged by 396.37% to $4.8 million in 2025, then tumbled by 40.75% to $2.8 million in 2026.
- Business Quant data shows TENX's Share-based Compensation at $2.8 million in Q1 2026, $4.8 million in Q4 2025, and $5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Tenax Therapeutics | 67,856.40 | 67,856.40 | - | 2.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.84 Mn |
| Mar 31, 2026 | 2.84 Mn |
| Dec 31, 2025 | 4.79 Mn |
| Dec 31, 2025 | 4.79 Mn |
| Sep 30, 2025 | 5.50 Mn |
| Sep 30, 2025 | 5.50 Mn |
| Jun 30, 2025 | 26.50 Mn |
| Jun 30, 2025 | 26.50 Mn |
| Mar 31, 2025 | 4.00 Mn |
| Mar 31, 2025 | 4.00 Mn |
| Dec 31, 2024 | 965,000.00 |
| Dec 31, 2024 | 965,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Dec 31, 2021 | -21.58 Mn |
| Dec 31, 2021 | -21.58 Mn |